<DOC>
	<DOCNO>NCT00138177</DOCNO>
	<brief_summary>This phase I trial study side effect best dose suberoylanilide hydroxamic acid give together fluorouracil , leucovorin , oxaliplatin treat patient progressive metastatic unresectable colorectal cancer solid tumor . Drugs use chemotherapy , suberoylanilide hydroxamic acid , fluorouracil , leucovorin , oxaliplatin , work different way stop growth tumor cell , either kill cell stop dividing . Suberoylanilide hydroxamic acid may also stop growth tumor cell block enzymes need cell growth . Giving one drug ( combination chemotherapy ) may kill tumor cell .</brief_summary>
	<brief_title>Suberoylanilide Hydroxamic Acid , Fluorouracil , Leucovorin , Oxaliplatin Treating Patients With Progressive Metastatic Unresectable Colorectal Cancer Other Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose suberoylanilide hydroxamic acid administer fluorouracil , leucovorin calcium , oxaliplatin patient progressive metastatic unresectable colorectal cancer solid tumor . SECONDARY OBJECTIVES : I . Determine toxicity regimen patient . II . Determine pharmacokinetics oxaliplatin , fluorouracil , suberoylanilide hydroxamic acid patient . OUTLINE : This dose-escalation study suberoylanilide hydroxamic acid ( SAHA ) . Patients receive oral SAHA twice daily day 1-3 . Patients also receive oxaliplatin IV 2 hour leucovorin calcium IV 2 hour day 4 follow fluorouracil IV 46 hour day 4-5 . Courses repeat every 14 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos SAHA maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . A total 10 patient treated MTD . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Histologically confirm colorectal cancer Metastatic unresectable disease OR diagnosis solid tumor No known brain metastasis ECOG 01 OR Karnofsky 70100 % Life expectancy &gt; 12 week Absolute neutrophil count ≥ 1,500/mm^3 WBC ≥ 3,000/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin normal AST ALT ≤ 3 time upper limit normal Creatinine normal OR creatinine clearance ≥ 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No ongoing active infection No neuropathy &gt; grade 1 No history allergic reaction attribute compound similar chemical biological composition study drug No psychiatric illness social situation would preclude study compliance No psychiatric illness social situation would preclude study compliance No uncontrolled illness Prior bevacizumab and/or cetuximab allow No concurrent routine prophylactic filgrastim ( GCSF ) sargramostim ( GMCSF ) More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) More 4 week since prior radiotherapy Recovered prior therapy At least 2 week since prior valproic acid No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>